- Donald Trump May Have Had His 'Oops' Moment Over Mexico
- Does Apple Have a Watch Problem?
- MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin
- Has Trump's Presidential Bid Already Backfired? A Billion-Dollar Brand Turned Toxic
- How Apple Music Could Overthrow Spotify as the World's Largest Streaming Service
American businesses are increasingly looking across the pond for opportunities to set up shop, according to a new study.
Ken Davis, CEO of Mount Sinai Health System, said that the Supreme Court's decision in favor of Obamacare in June likely saved certain hospital systems.
The Supreme Court's ruling to keep Obamacare intact was likely a savior for some for-profit hospital systems and could lead to more consolidation for insurance companies and hospital providers.
The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.
Celgene (CELG) shares are rising after the company announced a 10-year $1 billion drug development deal with Juno.
Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.
Pick up Gannett spinoff TEGNA, biotech Amgen, specialty retailer Cabela's and even Bank of America, recommends Bill Smead, fund manager for the Smead Value Fund.
Papa Johns is the latest big food brand to clean up its act and cut down on artificial ingredients as consumers become more health conscious.
Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.
New Sarepta CEO Ed Kaye filed for approval of eteplirsen with the FDA as promised, allowing him to check off a hugely important item on the company's to-do list.
A panel of investment experts discussed where to find income as it is a huge generator of long-term returns.
Seres Therapeutics (MCRB) shares are up over 90% in its first day of trading on the Nasdaq.
Alder Biopharmaceuticals (ALDR) shares are climbing after the company priced its secondary offering of 4.5 million shares at $44.50.
Celladon (CLDN) shares are falling more than 40% after the company announced that it's halting R&D as it prepares for a possible liquidation.
Valeant Pharmaceuticals (VRX) shares are declining after the company reportedly made a bid for animal health company Zoetis (ZTS).
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV